You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Microsatellite Instability High

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Trial in Kashiwa (HRO761,

Recruiting
  • MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
  • Kashiwa, Chiba, Japan
    Novartis Investigative Site
May 2, 2023

Microsatellite Instability in Colorectal Cancers

Completed
  • Colorectal Cancer
  • +4 more
  • Microsatellite instability analysis
  • Istanbul, Turkey
    Sultan 2. Abdulhamid Training and Research Hospital
Dec 5, 2021

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

Not yet recruiting
  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma
  • (no location specified)
Sep 26, 2023

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

Not yet recruiting
  • Diffuse Astrocytoma, IDH-Mutant
  • +20 more
  • NEO212 Oral Capsule
  • +8 more
  • (no location specified)
Sep 18, 2023

DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Feb 14, 2023

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

Recruiting
  • Colorectal Cancer
  • +3 more
  • Neoadjuvant therapy with PD-L1 inhibitor
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022

Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

Recruiting
  • Colorectal Carcinoma
  • Guangzhou, China
    Sun Yat-sen University
Dec 29, 2022

Solid Tumor Trial in Beijing (KN035)

Recruiting
  • Solid Tumor
  • KN035
  • Beijing, Beijing, China
    Peking University Cancer Hospital, Peking University
Apr 5, 2022

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

Recruiting
  • Colorectal Cancer
  • Microsatellite Instability High
  • PD-1 inhibitor plus VEGF inhibitors
  • Guangzhou, Guangdong, China
    651 Dongfeng Road East
May 27, 2022

Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma Trial in United States (MT-8421, Nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +10 more
  • Los Angeles, California
  • +4 more
Sep 5, 2023

Colorectal Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Colorectal Carcinoma
  • Pembrolizumab
  • (no location specified)
Mar 29, 2022

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

Not yet recruiting
  • Melanoma
  • +5 more
  • INCB 99280 with Ipilimumab
  • (no location specified)
Jun 9, 2023

Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)

Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022

Melanoma, NSCLC, Hepatocellular Carcinoma Trial in Pittsburgh (Nivolumab or Pembrolizumab (dependent upon approved indication),

Recruiting
  • Melanoma
  • +7 more
  • Nivolumab or Pembrolizumab (dependent upon approved indication)
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 10, 2022

Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) Trial in Gainesville, Jacksonville (LITT +

Recruiting
  • Melanoma
  • +14 more
  • LITT + Pembrolizumab
  • Gainesville, Florida
  • +1 more
Aug 22, 2022

Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High Trial in United States

Recruiting
  • Advanced or Metastatic Solid Tumors
  • +11 more
  • Tucson, Arizona
  • +11 more
Dec 2, 2022